- Home
- ALAR vs IMAB Comparison
ALAR vs IMAB Comparison
Compare ALAR & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- IMAB
- Stock Information
- Founded
- ALAR 2013
- IMAB 2014
- Country
- ALAR Israel
- IMAB United States
- Employees
- ALAR N/A
- IMAB N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- IMAB Health Care
- Exchange
- ALAR Nasdaq
- IMAB Nasdaq
- Market Cap
- ALAR 94.0M
- IMAB 79.9M
- IPO Year
- ALAR 2018
- IMAB 2020
- Fundamental
- Price
- ALAR $6.91
- IMAB $0.95
- Analyst Decision
- ALAR Strong Buy
- IMAB Strong Buy
- Analyst Count
- ALAR 2
- IMAB 3
- Target Price
- ALAR $24.00
- IMAB $8.00
- AVG Volume (30 Days)
- ALAR 116.1K
- IMAB 248.6K
- Earning Date
- ALAR 03-13-2025
- IMAB 03-13-2025
- Dividend Yield
- ALAR N/A
- IMAB N/A
- EPS Growth
- ALAR N/A
- IMAB N/A
- EPS
- ALAR 0.10
- IMAB N/A
- Revenue
- ALAR $31,561,000.00
- IMAB $569,464.00
- Revenue This Year
- ALAR $22.82
- IMAB N/A
- Revenue Next Year
- ALAR $9.87
- IMAB N/A
- P/E Ratio
- ALAR $7.03
- IMAB N/A
- Revenue Growth
- ALAR 40.80
- IMAB N/A
- 52 Week Low
- ALAR $6.78
- IMAB $0.84
- 52 Week High
- ALAR $46.69
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- ALAR 17.37
- IMAB 46.35
- Support Level
- ALAR $6.78
- IMAB $0.87
- Resistance Level
- ALAR $8.50
- IMAB $1.04
- Average True Range (ATR)
- ALAR 0.51
- IMAB 0.05
- MACD
- ALAR -0.24
- IMAB -0.00
- Stochastic Oscillator
- ALAR 3.25
- IMAB 47.00
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).